This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
CYNK-001
DrugBank Accession Number
DB15722
Background

CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
Not Available
External IDs
  • CYNK-001

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

CYNK-001 has the potential to inhibit viral infection by killing host cells through indirect immune responses. CYNK-001 expresses NKG2D and DNAM-1 receptors in addition to cytotoxicity receptors NKp30, NKp44, and NKp46. These receptors bind to the ligands and antigens expressed on infected cells, and initiate the release of perforin and granzyme B from the NK cell to induce cell death. In addition to being investigated for the treatment of acute myeloid leukemia, multiple myeloma, and glioblastoma multiforme, CYNK-001 is also being investigated for treating COVID-19.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Zhang J, Xie B, Hashimoto K: Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun. 2020 Jul;87:59-73. doi: 10.1016/j.bbi.2020.04.046. Epub 2020 Apr 22. [Article]
  2. Lifespan: CELULARITY INC. – CYNK-001 [Link]
  3. Oncology Nursing News: Novel Cancer Agent To Be Investigated for Coronavirus Treatment [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAnalgesics / Analgesics, Non-Narcotic / Blood Protein Disorders / Cardiovascular Disease (CVD) / Chemotherapy / Disorders, Lymphoproliferative / Hematologic Diseases / Hemorrhagic Disorders / Hemostatic Disorders / Immune System Diseases / Immunoproliferative Disorders / Multiple Myeloma (MM) / Neoplasms by Histologic Type / Neoplastic Disease / Paraproteinemias / Peripheral Nervous System Agents / Physiological Effects of Drugs / Plasma Cell Neoplasms / Sensory System Agents / Vascular Diseases1
1RecruitingTreatmentAcute Myeloid Leukemia (AML) / Alkylating Agents / Analgesics / Analgesics, Non-Narcotic / Anti-Infective Agents / Antimetabolites, Antineoplastic / Antiviral Agents / Hematologic Diseases / Immunologic Factors / Immunosuppressive Agents / Leukemia in Remission / Leukemias / Myeloid Leukemias / Neoplasms by Histologic Type / Neoplasms, Hematologic / Neoplastic Disease / Peripheral Nervous System Agents / Physiological Effects of Drugs / Refractory Acute Myeloid Leukemia (AML) / Relapsed Adult AML1
1TerminatedTreatmentAnalgesics / Analgesics, Non-Narcotic / Anti-Infective Agents / Antiviral Agents / Astrocytoma, Grade IV / Cyclophosphamide / Giant Cell Glioblastoma / Glioblastoma Multiforme (GBM) / Immunologic Factors / Immunosuppressive Agents / Molecular Mechanisms of Pharmacological Action / Peripheral Nervous System Agents / Physiological Effects of Drugs / Sensory System Agents1
1, 2Active Not RecruitingTreatmentAnalgesics / Anti-Infective Agents / Antimetabolites, Antineoplastic / Antiviral Agents / Coronaviridae Infections / Coronavirus Disease 2019 (COVID‑19) / Immunologic Diseases / Immunologic Factors / Infections, Coronavirus / Lung Disorder / Nidovirales Infections / Physiological Effects of Drugs / Pneumonia / Recurrent Upper and Lower Respiratory Tract Infections (RTIs) / Respiratory Distress Syndrome, Acute (ARDS) / Respiratory Tract Diseases / Severe Acute Respiratory Syndrome Coronavirus 2 / Viral Pneumonia / Virus Diseases / Virus Infection, RNA1
1, 2RecruitingTreatmentAstrocytoma, Grade IV / Giant Cell Glioblastoma / Glioblastoma Multiforme (GBM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at August 11, 2020 18:08 / Updated at August 13, 2020 07:02